Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.

Autor:	Talbot, Denis, Smith, Ian, Nicolson, Marianne, Powles, Trevor, Button, Diane, Walling, Jackie, Talbot, D C, Smith, I E, Nicolson, M C, Powles, T J, Button, D, Walling, J
Předmět:	ANTINEOPLASTIC agents BREAST tumors COMPARATIVE studies DOSE-effect relationship in pharmacology RESEARCH methodology MEDICAL cooperation ORAL drug administration RESEARCH EVALUATION research SULFONYLUREAS THERAPEUTICS
Zdroj:	Cancer Chemotherapy & Pharmacology; Sep1993, Vol. 31 Issue 5, p419-422, 4p
Abstrakt:	A total of 18 women with advanced breast cancer were treated with sulofenur [LY186641; N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea], a diarylsulfonylurea that has broad-spectrum activity against a number of murine mammary tumour xenografts. The dosage chosen on the basis of pre-clinical and phase I studies was 700 mg/m2 given orally once daily for 14 days, with treatments being repeated every 3 weeks. There was no response. All patients experienced at least grade 1 anaemia, and two patients developed symptomatic methaemoglobinaemia. Two patients developed grade 4 rises in serum liver-function values along with histological changes consistent with drug-induced toxicity. The mean plasma concentrations of 176 micrograms/ml were lower than the levels required to exert anti-tumour effect in the mouse model. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink